This bispecific antibody contains a first antigen binding moiety that specifically binds an epitope on human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and a second antigen binding moiety that specifically binds an epitope on a human programmed death 1 (PD-1) receptor, which can provide some pharmaceutical compositions as well as methods and kits for treating cancer. It is also capable of blocking both CTLA-4 and PD-1 pathways on T cell activation and resulting in enhanced T cell proliferation subsequently.
Download resources about recombinant antibody development and antibody engineering to boost your research.
There are currently no Customer reviews or questions for TRIAB-MZ012. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.